STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 (STOP-COVID19)
Covid19
About this trial
This is an interventional treatment trial for Covid19
Eligibility Criteria
Inclusion Criteria:
6.1. Inclusion criteria
• Male or female
- ≥16 years of age
- SARS-CoV-2 infection (clinically suspected+ or laboratory confirmed*).
- Admitted to hospital as in-patient less than 96 hours prior to randomisation^
Illness of any duration, and at least one of the following:
- Radiographic infiltrates by imaging (e.g. chest x-ray, computed tomography (CT) scan) OR
- Evidence of rales/crackles on physical examination OR
- Peripheral capillary oxygen saturation (SpO2) ≤94% on room air prior to randomization OR
- Requiring supplemental oxygen. OR
- Lymphocyte count <1 x 109 cells per litre (L)
- Participant (or legally authorized representative) provides written informed consent
- Able to take oral medication
Participant (or legally authorised representative) understands and agrees to comply with planned trial procedures.
Laboratory-confirmed: SARS-CoV-2 infection as determined by polymerase chain reaction (PCR), or other commercial or public health assay in any specimen < 96 hours prior to randomization.
Clinically suspected: in general, SARS-CoV-2 infection should be suspected when a patient presents with (i) typical symptoms (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and (ii) compatible chest X-ray findings (consolidation or ground-glass shadowing); and (iii) alternative causes have been considered unlikely or excluded (e.g. heart failure, influenza). However, the diagnosis remains a clinical one based on the opinion of the managing doctor
- Where a patient has been admitted to hospital for a non COVID-19 reason and develops COVID-19 symptoms whilst an in-patient, randomisation may occur up to 96 hours from onset of symptoms.
Exclusion Criteria:
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 5 times the upper limit of normal, result within 72 hours of randomization (the result closest to randomization should be used if several results are available).
- History of severe liver disease
- Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated Glomerular Filtration Rate < 30), result within 72 hours of randomization (the result closest to randomization should be used if several results are available)
- Absolute neutrophil count less than 1.0 x 109 cells per L within 72 hours of randomization (the result closest to randomization should be used if several results are available)
- Current treatments with potent Cyp3A4 inducers/inhibitors (e.g Itraconazole, Ketoconazole, diltiazem, verapamil, phenytoin or rifampicin)
- HIV treatments - current treatment with protease/integrase inhibitors or non-nucleoside reverse transcriptase inhibitors*
- Pregnant or breast feeding.
- Anticipated transfer to another hospital which is not a trial site within 24 hours.
- Allergy to Brensocatib
- Use of any investigational drug within five times of the elimination half-life after the last trial dose or within 30 days, whichever is longer. Co-enrolment with COVID-19 trials is allowed as per co-enrolment agreements and/or individual decision by the Chief Investigator.
Women of child-bearing potential must be willing to have pregnancy testing prior to trial entry.
*The Liverpool HIV checker (https://www.hiv-druginteractions.org/checker) should be used to check for any HIV drug interactions. Simvastatin could be used as a surrogate for Brensocatib as it metabolised similarly by CYP 3A4 pathway.
-
Sites / Locations
- NHS Grampian
- Royal United Hospitals Bath NHS Foundation Trust
- University Hospitals Birmingham NHS Foundation Trust
- Cardiff & Vale University Health Board
- NHS Tayside
- NHS Fife
- Frimley Health NHS Foundation Trust
- Princess Alexandra Hospital NHS Trust
- NHS Highland
- NHS Forth Valley
- University Hospitals of Leicester NHS Trust
- Liverpool University Hospitals NHS Foundation Trust
- Portsmouth Hospitals NHS Trust
- Sheffield Teaching Hospitals NHS Foundation Trust
- University Hospitals North Midlands NHS Trust
- NHS Lanarkshire
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Brensocatib
Placebo
Brensocatib oral tablet, 25mg once per day for 28 days
Placebo oral tablet, 25mg once per day for 28 days